Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Table of Contents

 1 Market Overview
    1.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product Introduction
    1.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size Forecast (2019-2030)
    1.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Trends & Drivers
        1.3.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industry Trends
        1.3.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers & Opportunity
        1.3.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges
        1.3.4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players Revenue Ranking (2023)
    2.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue by Company (2019-2024)
    2.3 Key Companies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product Offered
    2.5 Key Companies Time to Begin Mass Production of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service
    2.6 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Competitive Analysis
        2.6.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Cell Therapy
        3.1.2 Cell-derived Products
    3.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type
        3.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, by Type (2019-2030)
        3.2.3 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Large Pharmaceutical Company
        4.1.2 Small and Medium-sized Pharmaceutical Company
    4.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application
        4.2.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, by Application (2019-2030)
        4.2.3 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region
        5.1.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (2019-2024)
        5.1.3 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (2025-2030)
        5.1.4 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        5.2.2 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        5.3.2 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        5.4.2 Asia Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        5.5.2 South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        5.6.2 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
    6.3 United States
        6.3.1 United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        6.3.2 United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        6.4.2 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        6.5.2 China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        6.6.2 Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        6.7.2 South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        6.8.2 Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019-2030
        6.9.2 India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Lonza
        7.1.1 Lonza Profile
        7.1.2 Lonza Main Business
        7.1.3 Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.1.4 Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.1.5 Lonza Recent Developments
    7.2 uBriGene Biosciences International
        7.2.1 uBriGene Biosciences International Profile
        7.2.2 uBriGene Biosciences International Main Business
        7.2.3 uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.2.4 uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.2.5 uBriGene Biosciences International Recent Developments
    7.3 Thermo Fisher
        7.3.1 Thermo Fisher Profile
        7.3.2 Thermo Fisher Main Business
        7.3.3 Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.3.4 Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.3.5 Thermo Fisher Recent Developments
    7.4 Creative Biolabs
        7.4.1 Creative Biolabs Profile
        7.4.2 Creative Biolabs Main Business
        7.4.3 Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.4.4 Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.4.5 Creative Biolabs Recent Developments
    7.5 REPROCELL
        7.5.1 REPROCELL Profile
        7.5.2 REPROCELL Main Business
        7.5.3 REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.5.4 REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.5.5 REPROCELL Recent Developments
    7.6 ATCC
        7.6.1 ATCC Profile
        7.6.2 ATCC Main Business
        7.6.3 ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.6.4 ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.6.5 ATCC Recent Developments
    7.7 Beijing CytoNiche Biotech
        7.7.1 Beijing CytoNiche Biotech Profile
        7.7.2 Beijing CytoNiche Biotech Main Business
        7.7.3 Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.7.4 Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.7.5 Beijing CytoNiche Biotech Recent Developments
    7.8 OmniaBio
        7.8.1 OmniaBio Profile
        7.8.2 OmniaBio Main Business
        7.8.3 OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.8.4 OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.8.5 OmniaBio Recent Developments
    7.9 Histocell
        7.9.1 Histocell Profile
        7.9.2 Histocell Main Business
        7.9.3 Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.9.4 Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.9.5 Histocell Recent Developments
    7.10 FUJIFILM Diosynth Biotechnologies
        7.10.1 FUJIFILM Diosynth Biotechnologies Profile
        7.10.2 FUJIFILM Diosynth Biotechnologies Main Business
        7.10.3 FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.10.4 FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.10.5 FUJIFILM Diosynth Biotechnologies Recent Developments
    7.11 Taiwan Bio Therapeutics
        7.11.1 Taiwan Bio Therapeutics Profile
        7.11.2 Taiwan Bio Therapeutics Main Business
        7.11.3 Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.11.4 Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.11.5 Taiwan Bio Therapeutics Recent Developments
    7.12 Encell Co., Ltd.
        7.12.1 Encell Co., Ltd. Profile
        7.12.2 Encell Co., Ltd. Main Business
        7.12.3 Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.12.4 Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.12.5 Encell Co., Ltd. Recent Developments
    7.13 Mycenax
        7.13.1 Mycenax Profile
        7.13.2 Mycenax Main Business
        7.13.3 Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
        7.13.4 Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (US$ Million) & (2019-2024)
        7.13.5 Mycenax Recent Developments

 8 Industry Chain Analysis
    8.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industrial Chain
    8.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Model
        8.5.2 Sales Channel
        8.5.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Trends
 Table 2. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers & Opportunity
 Table 3. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Challenges
 Table 4. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints
 Table 5. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue by Company (2019-2024) & (US$ Million)
 Table 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Market Share by Company (2019-2024)
 Table 7. Key Companies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Manufacturing Base Distribution and Headquarters
 Table 8. Key Companies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product Type
 Table 9. Key Companies Time to Begin Mass Production of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service
 Table 10. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Companies Market Concentration Ratio (CR5 and HHI)
 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service as of 2023)
 Table 12. Mergers & Acquisitions, Expansion Plans
 Table 13. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
 Table 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (2019-2024) & (US$ Million)
 Table 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (2025-2030) & (US$ Million)
 Table 16. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Market Share in Value by Type (2019-2024)
 Table 17. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Market Share in Value by Type (2025-2030)
 Table 18. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
 Table 19. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (2019-2024) & (US$ Million)
 Table 20. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (2025-2030) & (US$ Million)
 Table 21. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Market Share in Value by Application (2019-2024)
 Table 22. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Market Share in Value by Application (2025-2030)
 Table 23. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region, (2019 VS 2023 VS 2030) & (US$ Million)
 Table 24. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (2019-2024) & (US$ Million)
 Table 25. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (2025-2030) & (US$ Million)
 Table 26. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (2019-2024) & (%)
 Table 27. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (2025-2030) & (%)
 Table 28. Key Countries/Regions Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
 Table 29. Key Countries/Regions Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2024) & (US$ Million)
 Table 30. Key Countries/Regions Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2025-2030) & (US$ Million)
 Table 31. Lonza Basic Information List
 Table 32. Lonza Description and Business Overview
 Table 33. Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 34. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Lonza (2019-2024)
 Table 35. Lonza Recent Developments
 Table 36. uBriGene Biosciences International Basic Information List
 Table 37. uBriGene Biosciences International Description and Business Overview
 Table 38. uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 39. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of uBriGene Biosciences International (2019-2024)
 Table 40. uBriGene Biosciences International Recent Developments
 Table 41. Thermo Fisher Basic Information List
 Table 42. Thermo Fisher Description and Business Overview
 Table 43. Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 44. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Thermo Fisher (2019-2024)
 Table 45. Thermo Fisher Recent Developments
 Table 46. Creative Biolabs Basic Information List
 Table 47. Creative Biolabs Description and Business Overview
 Table 48. Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 49. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Creative Biolabs (2019-2024)
 Table 50. Creative Biolabs Recent Developments
 Table 51. REPROCELL Basic Information List
 Table 52. REPROCELL Description and Business Overview
 Table 53. REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 54. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of REPROCELL (2019-2024)
 Table 55. REPROCELL Recent Developments
 Table 56. ATCC Basic Information List
 Table 57. ATCC Description and Business Overview
 Table 58. ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 59. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of ATCC (2019-2024)
 Table 60. ATCC Recent Developments
 Table 61. Beijing CytoNiche Biotech Basic Information List
 Table 62. Beijing CytoNiche Biotech Description and Business Overview
 Table 63. Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 64. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Beijing CytoNiche Biotech (2019-2024)
 Table 65. Beijing CytoNiche Biotech Recent Developments
 Table 66. OmniaBio Basic Information List
 Table 67. OmniaBio Description and Business Overview
 Table 68. OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 69. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of OmniaBio (2019-2024)
 Table 70. OmniaBio Recent Developments
 Table 71. Histocell Basic Information List
 Table 72. Histocell Description and Business Overview
 Table 73. Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 74. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Histocell (2019-2024)
 Table 75. Histocell Recent Developments
 Table 76. FUJIFILM Diosynth Biotechnologies Basic Information List
 Table 77. FUJIFILM Diosynth Biotechnologies Description and Business Overview
 Table 78. FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 79. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of FUJIFILM Diosynth Biotechnologies (2019-2024)
 Table 80. FUJIFILM Diosynth Biotechnologies Recent Developments
 Table 81. Taiwan Bio Therapeutics Basic Information List
 Table 82. Taiwan Bio Therapeutics Description and Business Overview
 Table 83. Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 84. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Taiwan Bio Therapeutics (2019-2024)
 Table 85. Taiwan Bio Therapeutics Recent Developments
 Table 86. Encell Co., Ltd. Basic Information List
 Table 87. Encell Co., Ltd. Description and Business Overview
 Table 88. Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 89. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Encell Co., Ltd. (2019-2024)
 Table 90. Encell Co., Ltd. Recent Developments
 Table 91. Mycenax Basic Information List
 Table 92. Mycenax Description and Business Overview
 Table 93. Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Products, Services and Solutions
 Table 94. Revenue (US$ Million) in Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Business of Mycenax (2019-2024)
 Table 95. Mycenax Recent Developments
 Table 96. Key Raw Materials Lists
 Table 97. Raw Materials Key Suppliers Lists
 Table 98. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Downstream Customers
 Table 99. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Distributors List
 Table 100. Research Programs/Design for This Report
 Table 101. Key Data Information from Secondary Sources
 Table 102. Key Data Information from Primary Sources
 Table 103. Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product Picture
 Figure 2. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
 Figure 3. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value (2019-2030) & (US$ Million)
 Figure 4. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Report Years Considered
 Figure 5. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players Revenue Ranking (2023) & (US$ Million)
 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue in 2023
 Figure 7. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 8. Cell Therapy Picture
 Figure 9. Cell-derived Products Picture
 Figure 10. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 11. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value Market Share by Type, 2023 & 2030
 Figure 12. Product Picture of Large Pharmaceutical Company
 Figure 13. Product Picture of Small and Medium-sized Pharmaceutical Company
 Figure 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
 Figure 15. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value Market Share by Application, 2023 & 2030
 Figure 16. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value (2019-2030) & (US$ Million)
 Figure 17. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030
 Figure 18. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 19. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030
 Figure 20. Asia Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 21. Asia Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Region (%), 2023 VS 2030
 Figure 22. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 23. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030
 Figure 24. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 25. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Country (%), 2023 VS 2030
 Figure 26. Key Countries/Regions Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value (%), (2019-2030)
 Figure 27. United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 28. United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
 Figure 29. United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (%), 2023 VS 2030
 Figure 30. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 31. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
 Figure 32. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (%), 2023 VS 2030
 Figure 33. China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 34. China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
 Figure 35. China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (%), 2023 VS 2030
 Figure 36. Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 37. Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
 Figure 38. Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (%), 2023 VS 2030
 Figure 39. South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 40. South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
 Figure 41. South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (%), 2023 VS 2030
 Figure 42. Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 43. Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
 Figure 44. Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (%), 2023 VS 2030
 Figure 45. India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value, (2019-2030) & (US$ Million)
 Figure 46. India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Type (%), 2023 VS 2030
 Figure 47. India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Sales Value by Application (%), 2023 VS 2030
 Figure 48. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industrial Chain
 Figure 49. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Manufacturing Cost Structure
 Figure 50. Channels of Distribution (Direct Sales, and Distribution)
 Figure 51. Bottom-up and Top-down Approaches for This Report
 Figure 52. Data Triangulation
 Figure 53. Key Executives Interviewed